Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers

Results from mTNBC and MBC studies continues to be positive with the first patient now at almost five months of treatment showing zero CTC, EMT and CAML. Seven patients have been enrolled to date ...
February 20, 2020 14:00 ET | Source: CytoDyn Inc.

CytoDyn Interview to Air on Bloomberg International on the RedChip Money Report

VANCOUVER, Washington, Feb. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
February 14, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
February 12, 2020 08:58 ET | Source: CytoDyn Inc.

CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group

VANCOUVER, Washington, Feb. 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
February 10, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on February 11, 2020

VANCOUVER, Washington, Feb. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
February 06, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers

VANCOUVER, Washington, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5...
February 03, 2020 13:28 ET | Source: CytoDyn Inc.

CytoDyn to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
January 31, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

VANCOUVER, Washington, Jan. 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
January 27, 2020 09:00 ET | Source: CytoDyn Inc.

CytoDyn Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn...
January 27, 2020 06:00 ET | Source: CytoDyn Inc.

CytoDyn Announces CROI’s Acceptance of Late-Breaking Abstract by Dr. Jonah Sacha for use of Leronlimab as PrEP

Acceptance underscores the scientific community’s recognition of leronlimab as a potential HIV prophylactic CytoDyn is currently partnered with the Thai Red Cross AIDS Research Centre (TRCARC) to...